GE Healthcare will exclusively distribute DiscoverX's HitHunter cAMP enzyme fragment complementation-based assays worldwide, the companies said this week.

The deal also expands GE Healthcare's exclusive rights to market the rest of DiscoverX' HitHunter product portfolio to regions outside of North America and Europe, a DiscoverX executive said.

The deal is a significant marketing shot in the arm for DiscoverX's flagship product line, and it also allows DiscoverX to focus its resources more on scientific collaborations, R&D, and product development.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In a survey, about half of Canadian government scientists say they still feel as though they cannot speak freely, ScienceInsider reports.

Clinicians in China are moving ahead with a number of CRISPR trials, NPR reports, as the US embarks on its first.

The Atlantic reports that biohacker Josiah Zayner regrets injecting himself with the CRISPR gene-editing tool on stage.

In Nature this week: genomic approaches applied to study Neolithic and Bronze Age Europeans, and more.